Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009
DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018
BioCryst Receives First Peramivir Order From U.S. Government
Interleukin Genetics Announces Conference Call to Discuss Third Quarter 2009 Results
Chelation Therapy Drug Found Safe and Beneficial for Children With Autism
DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix
MedPage Today(R) and ABC News Premiere 'Doctor's Orders' Segment on Good Morning America Weekend
ETEX Corporation Announces Distribution Agreement with Alphatec Spine
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Terms and conditions, including restrictions on redistribution, apply. Copyright © 1996-2009 PR Newswire Association LLC. All Rights Reserved. A United Business Media company.